PCN38 COST-ANALYSIS OF XELOXVS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65196-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)65196-0/fulltext
Section Title :
Section Order :
356
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65196-0&doi=10.1016/S1098-3015(10)65196-0